CORT Shares Plummet On FDA’s Drug Rejection Letter Reveal — Here’s What Retail Has To Say

Stocktwits

Shares of Corcept Therapeutics Inc. (CORT) fell 11% on Friday after the U.S. Food and Drug Administration (FDA) published its amended letter to the company pertaining to refusal of approval for its drug Relacorilant.

As per the letter, the results of the late-stage trials submitted by the company are insufficient to demonstrate effectiveness in treating patients with hypercortisolism. The agency also flagged risks of drug induced liver injury

“During the pre-submission meetings, we informed you on several occasions of our concerns about the adequacy of the clinical development program to assess the effect of Relacorilant on hypertension in the intended population including the design of CORT125134-455, and to expect significant review issues if you were to submit your application,” the letter said.

The agency further asked for new clinical data to address the concerns raised and also risk mitigation strategies for drug-induced liver injury in the letter.

FDA Rejects Drug

The FDA refused approval for the drug in December.

“We are surprised and disappointed by this outcome,” CEO Joseph K. Belanoff had then said.

The company also committed to meeting with the FDA to discuss a path forward.

Relacorilant Uses

Corcept is studying Relacorilant in both hypercortisolism and ovarian cancer. Hypercortisolism, or Cushing syndrome, is a disorder caused by prolonged, excessive exposure to cortisol, resulting in symptoms like weight gain, thin skin, purple stretch marks, and hypertension.

How Did Stocktwits Users React?

On Stocktwits, retail sentiment around CORT stock remained within the ‘bearish’ territory while retail chatter improved from ‘extremely low’ to ‘low’ levels over the past 24 hours.

A Stocktwits user said that the company might have to re-do a full late-stage trial for approval.

https://www.stocktwits.com/Nano_Nick/message/643456742

Another highlighted that FDA’s rejection of Relacorilant is old news and the market has already overreacted to it.

https://www.stocktwits.com/UnoffensiveName/message/643437277

Yet another compared the experimental drug with approved Cushing’s syndrome treatment Recorlev. “Either Recorlev should be immediately pulled from market for being 10x more dangerous than Relacorilant, or Relacorilant should be approved,” they wrote.

https://www.stocktwits.com/moorenard1/message/643423680

CORT stock has dropped about 43% over the past 12 months.

Risk Warnings and Disclaimers

You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.

Add to Favorites

Tesla and AMD among market cap stock movers on Friday

Investing.com

Anbio Biotechnology Inc.

-15.39%

Thermo Fisher Scientific

-0.85%

Two Harbors Investment Corp.

Friday’s market has seen swings in various stocks based on news and other factors. Today, stocks like Tesla (TSLA) and Advanced Micro Devices ( are rallying, while companies like KLA-Tencor (KLAC) are facing setbacks. Below are highlights of some of the biggest stock movers, from mega-caps to small caps.

Mega-Cap Movers ($200 billion+ market cap)

KLA-Tencor (KLAC) -11.29%
Advanced Micro Devices (AMD); AMD (AMD) Quickly Falls 5.1% -4.03%
Palantir Technologies (PLTR) -2.07%
Lam Research (LRCX) -2.58%
American Express (AXP) -2.37%
Thermo Fisher Scientific (TMO) -1.97%
Tesla (TSLA); Elon Musk’s SpaceX Is Said To Consider Merger With Tesla Or xAI +3.95%
Metropcs Communications (TMUS) +3.55%

Large-Cap Stock Movers ($10-$200 billion market cap)

Unity Software (U) -21.59%
Rocket Companies (RKT) -14.83%
AngloGold Ashanti (AU) -9.37%
Coeur d’Alene Mines (CDE) -8.59%
Yandex (NBIS) -8.75%
Hecla Mining (HL) -7.73%
Charter Communications (CHTR); Charter shares rise over 6% as earnings beat offsets revenue miss +10.14%
SanDisk Corp-Exch (SNDK) +12.9%
Deckers Outdoor (DECK) +14.83%
Lumentum Holdings (LITE) +5.86%

Mid-Cap Stock Movers ($2-$10 billion market cap)

Pennymac Financial Services (PFSI) -36.25%
IES Holdings (IESC) -15.19%
Cavco Industries (CVCO); Cavco Industries shares slip 4% as Q3 earnings, revenue fall short of estimates -16.32%
Sanmina-SCI (SANM) -10.47%
Corcept Therapeutics (CORT) -12.64%
Mudrick Capital (HYMC) -8.11%
TFS Financial (TFSL); TFS Financial shares fall as first quarter earnings miss estimates -7.49%
Applied Optoelectronics (AAOI) +10.21%
Robert Half International (RHI); Robert Half shares surge after beating Q4 expectations +22.02%

Small-Cap Stock Movers ($300 million-$2 billion market cap)

TechCreate (TCGL) +155.33%
Lexicon Pharmaceuticals (LXRX); Lexicon Pharmaceuticals launches public offering of common stock -21.18%
Junee (SUPX); SuperX begins production at Japan supply center, secures orders -20.23%
Beazer Homes USA (BZH) -14.21%
Gores Holdings IV (UWMC) -14.12%
Two Harbors Investment (TWO) -14.3%
Red Rock Acquisition (NAMM) -14.53%
Oxford Lane Capital (OXLC) -14.02%
Anbio Biotechnology (NNNN) -11.11%
AXT (AXTI) +18.19%

For real-time, market-moving news, join Investing Pro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Risk Warnings and Disclaimers

Add to Favorites

Alibaba and Facebook among market cap stock movers on Thursday

Investing.com

SKYX Platforms

-6.38%

Inflection Point Acquisition Corp. II

-9.40%

Old Republic International

Thursday’s market has seen swings in various stocks based on news and other factors. Today, stocks like Alibaba (BABA) and Facebook (META) are rallying, while stocks like Abbott Laboratories (ABT) are falling. Below are highlights of some of the biggest stock movers, from mega-caps to small caps.

Mega-Cap Movers ($200 billion+ market cap)

Facebook (META); China, US sign off on TikTok US spinoff - Semafor: +5.07%
Alibaba-exch (BABA): +5.76%
Tesla Motors (TSLA): +3.49%
Procter Gamble (PG): +3.12%
Oracle Corp (ORCL): +2.98%
American Express (AXP): +2.42%
Wells Fargo (WFC): +3.0%
General Electric (GE): -5.84%
Abbott Laboratories (ABT): -10.05%
Salesforce Com (CRM): +2.39%

Large-Cap Stock Movers ($10-$200 billion market cap)

Regencell Bioscience Holdings (RGC): +36.47%
New Providence Acquisition Corp N (ASTS); AST SpaceMobile to launch BlueBird 7 satellite in February: +13.56%
Coeur dAlene Mines Corp (CDE): +11.98%
Fortress Value Acquisition Corp (MP): +9.6%
Arista Networks (ANET): +8.89%
Hecla Mining Comp (HL): +8.78%
Datadog Inc (DDOG); Stifel upgrades Datadog stock rating to Buy on expected Q4 beat: +7.46%
Old Republic International (ORI); Old Republic misses earnings estimates despite revenue growth: -9.95%
Figure Technology Solutions Ltd (FIGR): -8.75%
Mccormick & Co (MKC); McCormick appoints two new directors as board veterans set to retire: -8.49%

Mid-Cap Stock Movers ($2-$10 billion market cap)

Evolution Metals Tech (EMAT): +20.4%
Inflection Point Acquisition II (USAR); USA Rare Earth selects Fluor, WSP as partners for Texas project: +19.89%
Plug Power (PLUG): +16.4%
Mudrick Capital A (HYMC): +16.22%
Corcept Therapeutics (CORT); Corcept’s relacorilant shows 35% reduction in ovarian cancer deaths: +14.11%
Enphase Energy Inc (ENPH): +12.57%
Sunrun Inc (RUN): +9.76%
CF Acquisition Corp VI (RUMBW): +9.47%
TECO Energy Inc-Exch (TE): +12.08%
Inspire Medical Systems Inc (INSP); Oppenheimer downgrades Inspire Medical stock on CMS reimbursement reversal: -11.78%

Small-Cap Stock Movers ($300 million-$2 billion market cap)

Ambitions Enterprise Management Co (AHMA): +38.39%
CF Acquisition V (SATL): +27.99%
Sizzle Acquisition (CRML): +25.61%
SQL Technologies (SKYX): +24.4%
HCM II Acquisition (IMSR); Terrestrial Energy signs DOE agreement for IMSR fuel production: +20.3%
Burning Rock Biotech Ltd (BNR): +19.74%
Roth CH Acquisition V (NUAI): +19.71%
Redwire (RDW): +17.79%
Rich Sparkle Holdings (ANPA): +16.05%
Quartet Merger C (PANL): +19.19%

For real-time, market-moving news, join Investing Pro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Risk Warnings and Disclaimers

Add to Favorites

Why Did Corcept Therapeutics Stock Surge Over 14% Today?

Stocktwits

Corcept Therapeutics

-1.40%

Corcept Therapeutics Inc. (CORT) on Thursday announced positive clinical results from its Phase 3 ROSELLA study evaluating the experimental drug relacorilant combined with nab-paclitaxel chemotherapy in women with platinum-resistant ovarian cancer.

The company said the study hit its key survival goal, underscoring potential new hope for patients.

Positive Survival Results

In the ROSELLA trial, patients receiving relacorilant with nab-paclitaxel saw their risk of death drop by about 35% compared with those given the chemotherapy alone.

Median overall survival was 16.0 months for the combination versus 11.9 months for the group that received nab-paclitaxel alone, the company said.

Following the results, Corcept stock traded over 14% higher on Thursday morning. On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘bearish’ territory the previous day. Message volume changed to ‘low’ from ‘extremely low’ levels in 24 hours.

Progression-Free Survival

Earlier data from the same trial showed a roughly 30% reduction in the risk of disease progression for participants treated with relacorilant plus nab-paclitaxel. Safety findings for the combination therapy align with established profiles, with no new adverse events emerging, suggesting the drug can deliver a meaningful clinical benefit without adding extra risk.

“The addition of relacorilant to nab-paclitaxel, a trusted and effective chemotherapy, is positioned to become a new standard-of-care treatment for patients with platinum-resistant ovarian cancer, due to its overall survival benefit, well-tolerated side effect profile and oral administration.”

-Alexander B. Olawaiye, Principal Investigator, ROSELLA Trial

ROSELLA enrolled 381 women with platinum-resistant ovarian cancer across multiple regions, including the United States, Europe, South Korea, Brazil, Argentina, Canada, and Australia.

CORT stock has declined by 31% in the last 12 months.

Risk Warnings and Disclaimers

Add to Favorites

Alibaba and Regencell among market cap stock movers on Thursday

Investing.com

Old Republic International

Thursday’s market has seen swings in various stocks based on news and other factors. Today, stocks like Alibaba (BABA) and Regencell Bioscience Holdings (RGC) are rallying, while stocks like Abbott Laboratories (ABT) are falling. Below are highlights of some of the biggest stock movers, from mega-caps to small caps.

Mega-Cap Movers (Market Cap:$200 billion USD or higher)

Abbott Laboratories (ABT); -7.4%
General Electric (GE); -6.13%
Facebook Inc (META); China, US sign off on TikTok US spinoff; +3.78%
Oracle Corp (ORCL); +2.04%
Procter Gamble (PG); +2.61%
Alibaba-exch (BABA); +7.04%
Lam Research Corp (LRCX); -2.42%

Large-Cap Stock Movers (Market Cap:$10-$200 billion USD)

Regencell Bioscience Holdings (RGC); +30.53%
Old Republic International (ORI); Old Republic misses earnings estimates despite revenue growth; -10.92%
Coeur dAlene Mines Corp (CDE); +10.52%
Arista Networks (ANET); +8.19%
Moderna (MRNA); +7.57%
Karman Holdings (KRMN); Karman to acquire Seemann Composites and MSC for $220 million; +5.95%
Datadog Inc (DDOG); Stifel upgrades Datadog stock rating to Buy on expected Q4 beat; +5.76%
Kratos Defense & (KTOS); -5.42%
Vector Acquisition (RKLB); Rocket Lab completes first launch of 2026, deploys satellites for Open Cosmos; -4.69%
Mccormick & Co (MKC); McCormick appoints two new directors as board veterans set to retire; -6.05%

Mid-Cap Stock Movers (Market Cap:$2-$10 billion USD)

Grail (GRAL); +16.29%
Corcept Therapeutics (CORT); Corcept’s relacorilant shows 35% reduction in ovarian cancer deaths; +14.68%
Sustainable Opportunities Acqui (TMC); TMC USA files first consolidated seabed mining application with NOAA; +11.19%
Plug Power (PLUG); +10.82%
Lemonade Inc (LMND); +10.09%
Pattern Group Inc (PTRN); +9.58%
Iridium Communications (IRDM); +6.27%
Inflection Point Acquisition II (USAR); USA Rare Earth selects Fluor, WSP as partners for Texas project; +20.54%
CF Acquisition Corp VI (RUMBW); +15.08%
Chenghe Acquisition II (PLBL); -8.32%

Small-Cap Stock Movers (Market Cap:$300 million - $2 billion USD)

Rich Sparkle Holdings (ANPA); +57.86%
Roth CH Acquisition V (NUAI); +32.31%
SQL Technologies (SKYX); +21.2%
HCM II Acquisition (IMSR); Terrestrial Energy signs DOE agreement for IMSR fuel production; +14.71%
LSI Industries Inc (LYTS); LSI Industries shares edge up as second quarter results meet expectations; +13.25%
Spring Valley Acquisition III (SVAC); +15.99%
Sizzle Acquisition (CRML); +15.42%
Eagle Bancorp (EGBN); Eagle Bancorp shares jump after surprise profit, revenue beat; +19.02%
NVE Corp (NVEC); NVE Corp reports 23% revenue jump in third quarter; +16.99%
POET Tech NAQ (POET); POET Technologies raises $150 million in share offering; -13.26%

For real-time, market-moving news, join Investing Pro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Risk Warnings and Disclaimers

Add to Favorites

Corcept Therapeutics stock soars after cancer drug meets survival endpoint

Investing.com

Amazon

-2.36%

Advanced Micro Devices

Investing.com -- Corcept Therapeutics (NASDAQ:CORT) stock surged 45% Thursday after the company announced its Phase 3 trial for relacorilant in platinum-resistant ovarian cancer met its overall survival primary endpoint.

The pivotal ROSELLA trial showed patients treated with relacorilant in addition to nab-paclitaxel chemotherapy experienced a 35% reduction in the risk of death compared to those receiving nab-paclitaxel alone. Median overall survival reached 16.0 months for patients on the combination therapy versus 11.9 months for those on nab-paclitaxel monotherapy, representing a 4.1-month improvement.

This success follows the company’s previous announcement that the trial also met its other primary endpoint of improved progression-free survival. Patients receiving the combination therapy showed a 30% reduction in disease progression risk.

Notably, the drug combination was well-tolerated, with adverse events comparable to those seen in the nab-paclitaxel monotherapy arm, indicating relacorilant provided its benefits without increasing safety concerns.

The U.S. Food and Drug Administration is currently reviewing relacorilant’s New Drug Application with a target action date of July 11, 2026. The European Medicines Agency is also reviewing a Marketing Authorization Application for the treatment.

"The addition of relacorilant to nab-paclitaxel, a trusted and effective chemotherapy, is positioned to become a new standard-of-care treatment for patients with platinum-resistant ovarian cancer, due to its overall survival benefit, well tolerated side effect profile and oral administration," said Alexander B. Olawaiye, Director of gynecological cancer research at Magee-Women’s Hospital of the University of Pittsburgh and Principal Investigator in the ROSELLA trial.

Corcept is also studying relacorilant in other solid tumors, including platinum-sensitive ovarian, endometrial, cervical, pancreatic and prostate cancers.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Risk Warnings and Disclaimers

Add to Favorites

Q3 Earnings Roundup: Zoetis (NYSE:ZTS) And The Rest Of The Branded Pharmaceuticals Segment

Stock Story

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q3, starting with Zoetis .

Looking ahead, the branded pharmaceutical industry is positioned for tailwinds from advancements in precision medicine, increasing adoption of AI to enhance drug development efficiency, and growing global demand for treatments addressing chronic and rare diseases. However, headwinds include heightened regulatory scrutiny, pricing pressures from governments and insurers, and the looming patent cliffs for key blockbuster drugs. Patent cliffs bring about competition from generics, forcing branded pharmaceutical companies back to the drawing board to find the next big thing.

The 10 branded pharmaceuticals stocks we track reported a satisfactory Q3. As a group, revenues beat analysts’ consensus estimates by 2.5%.

Thankfully, share prices of the companies have been resilient as they are up 8.5% on average since the latest earnings results.

Zoetis

Originally spun off from Pfizer in 2013 as the world's largest pure-play animal health company, Zoetis discovers, develops, and sells medicines, vaccines, diagnostic products, and services for pets and livestock animals worldwide.

Zoetis reported revenues of $2.4 billion, flat year on year. This print was in line with analysts’ expectations, but overall, it was a slower quarter for the company with full-year revenue guidance slightly missing analysts’ expectations and revenue in line with analysts’ estimates.

The stock is down 14% since reporting and currently trades at $124.18.

Best Q3: Eli Lilly

Founded in 1876 by a Civil War veteran and pharmacist frustrated with the poor quality of medicines, Eli Lilly discovers, develops, and manufactures pharmaceutical products for conditions including diabetes, obesity, cancer, immunological disorders, and neurological diseases.

Eli Lilly reported revenues of $17.6 billion, up 53.9% year on year, outperforming analysts’ expectations by 9.7%. The business had a stunning quarter with a solid beat of analysts’ revenue estimates and full-year revenue guidance exceeding analysts’ expectations.

Eli Lilly pulled off the fastest revenue growth among its peers. The market seems happy with the results as the stock is up 28.3% since reporting. It currently trades at $1,041.

Corcept

Focusing on the powerful stress hormone that affects everything from metabolism to immune function, Corcept Therapeutics develops and markets medications that modulate cortisol to treat endocrine disorders, cancer, and neurological diseases.

Corcept reported revenues of $207.6 million, up 13.7% year on year, falling short of analysts’ expectations by 4%. It was a softer quarter as it posted full-year revenue guidance missing analysts’ expectations and a significant miss of analysts’ revenue estimates.

Corcept delivered the highest full-year guidance raise but had the weakest performance against analyst estimates in the group. As expected, the stock is down 50.7% since the results and currently trades at $35.05.

Read our full analysis of Corcept’s results here.

Merck

With roots dating back to 1891 and a portfolio that includes the blockbuster cancer immunotherapy Keytruda, Merck develops and sells prescription medicines, vaccines, and animal health products across oncology, infectious diseases, cardiovascular, and other therapeutic areas.

Merck reported revenues of $17.28 billion, up 3.7% year on year. This result beat analysts’ expectations by 1.8%. Overall, it was a strong quarter as it also logged a solid beat of analysts’ constant currency revenue estimates and a beat of analysts’ EPS estimates.

The stock is up 26.1% since reporting and currently trades at $109.15.

Read our full, actionable report on Merck here, it’s free.

Bristol-Myers Squibb

With roots dating back to 1887 and a transformative merger in 1989 that gave the company its current name, Bristol-Myers Squibb discovers, develops, and markets prescription medications for serious diseases including cancer, blood disorders, immunological conditions, and cardiovascular diseases.

Bristol-Myers Squibb reported revenues of $12.22 billion, up 2.9% year on year. This print topped analysts’ expectations by 3.7%. It was a very strong quarter as it also recorded a solid beat of analysts’ revenue estimates and an impressive beat of analysts’ full-year EPS guidance estimates.

The stock is up 27.6% since reporting and currently trades at $54.35.

Read our full, actionable report on Bristol-Myers Squibb here, it’s free.

Risk Warnings and Disclaimers

Add to Favorites